CD274 and non-small cell lung carcinoma: In this real-world cohort of stage I-III resectable NSCLC patients, we report that the addition of PD-(L)1 blockade to chemotherapy was associated with an significantly increased MPR rate and a numerically higher pCR rate in comparison to chemotherapy alone (MPR, 75.0% vs. 38.7%; pCR, 33.3% vs. 12.9%), which favored PD-(L)1 blockade plus chemotherapy over chemotherapy alone.